Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.224
Neutral
RSI(14)
50.609
Neutral
STOCH(KDJ)(9,3,3)
15.160
Sell
ATR(14)
0.330
Low Volatility
CCI(14)
-95.440
Neutral
Williams %R
96.968
Oversold
TRIX(12,20)
0.971
Sell
StochRSI(14)
0.000
Sell
Opus Genetics Inc
IRD4.370USD
-0.150-3.32%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
868.17KMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Opus Genetics Inc
Currency: USD Updated: 2026-03-27Key Insights
Opus Genetics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 81 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.54.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Opus Genetics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Opus Genetics Inc Highlights
StrengthsRisks
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Growing
The company is in a growing phase, with the latest annual income totaling USD 14.20M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 14.20M.
Undervalued
The company’s latest PE is -5.46, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 20.10M shares, increasing 4.06% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 2.32M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.59.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
9.538
Target Price
+111.03%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Opus Genetics Inc is 7.70, ranking 93 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 3.87M, representing a year-over-year decrease of 10.16%, while its net profit experienced a year-over-year decrease of 52.97%.
Score
Financials
8.10
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.96
Operational Efficiency
10.00
Growth Potential
6.22
Shareholder Returns
7.20
Opus Genetics Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Opus Genetics Inc is 6.93, ranking 104 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -5.46, which is -220.50% below the recent high of 6.58 and -29.33% above the recent low of -7.06.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 81/157
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Opus Genetics Inc is 8.33, ranking 41 out of 157 in the Pharmaceuticals industry. The average price target is 8.00, with a high of 9.00 and a low of 6.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
9.538
Target Price
+119.27%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Opus Genetics Inc
IRD
13
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Vertex Pharmaceuticals Inc
VRTX
34
Eli Lilly and Co
LLY
34
Gilead Sciences Inc
GILD
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Opus Genetics Inc is 7.14, ranking 33 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 5.16 and the support level at 3.69, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
4.544
Sell
MA10
4.634
Sell
MA20
4.682
Sell
MA50
3.668
Buy
MA100
2.865
Buy
MA200
2.120
Buy
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Opus Genetics Inc is 3.00, ranking 93 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 29.15%, representing a quarter-over-quarter increase of 3.02%. The largest institutional shareholder is The Vanguard, holding a total of 2.32M shares, representing 3.26% of shares outstanding, with 49.67% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Foundation Fighting Blindness Inc
Nantahala Capital Management, LLC
Perceptive Advisors LLC
Bios Equity Partners, LP.
Gallagher (Cam S)
Mink Brook Asset Management LLC
Opaleye Management Inc.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Opus Genetics Inc is 2.77, ranking 119 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.54. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.53
VaR
+6.48%
240-Day Maximum Drawdown
+24.35%
240-Day Volatility
+102.31%
Return
Best Daily Return
60 days
+16.67%
120 days
+16.75%
5 years
+20.51%
Worst Daily Return
60 days
-7.60%
120 days
-9.75%
5 years
-20.83%
Sharpe Ratio
60 days
+4.09
120 days
+2.70
5 years
+0.31
Risk Assessment
Maximum Drawdown
240 days
+24.35%
3 years
+88.25%
5 years
+88.89%
Return-to-Drawdown Ratio
240 days
+21.11
3 years
-0.11
5 years
-0.03
Skewness
240 days
+0.76
3 years
+0.28
5 years
+0.45
Volatility
Realised Volatility
240 days
+102.31%
5 years
+89.91%
Standardised True Range
240 days
+3.45%
5 years
+4.35%
Downside Risk-Adjusted Return
120 days
+618.04%
240 days
+618.04%
Maximum Daily Upside Volatility
60 days
+70.80%
Maximum Daily Downside Volatility
60 days
+43.11%
Liquidity
Average Turnover Rate
60 days
+0.91%
120 days
+1.68%
5 years
--
Turnover Deviation
20 days
-59.43%
60 days
-8.12%
120 days
+69.73%
Peer Comparison
Pharmaceuticals
Opus Genetics Inc
IRD
6.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Innoviva Inc
INVA
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
